Ciphergen Biosystems, Inc.

Results on biomarkers for early diagnosis of Alzheimer Disease announced

Published in Physician Law Weekly, August 18th, 2004

Ciphergen Biosystems, Inc., (NASDAQ:CIPH) announced that Prof. Kaj Blennow from the University of Gothenburg presented encouraging data from a comprehensive clinical study of human cerebral spinal fluid (CSF) comparing very mild Alzheimer Disease patients with normal individuals and non-AD dementia controls comprising a total of 236 samples.

Scientists at Ciphergen's Diagnostics Division discovered over 40 biomarkers that were either increased or decreased in Alzheimer Disease and considered statistically meaningful. These biomarkers encompass many different aspects of AD neuropathology, which make them potentially useful for further research into disease mechanism....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly

Source: Physician Law Weekly (2004-08-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry